Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 251 (LINC00251)
- Target
- LINC00251
- Molecular classification
- Long non-coding RNA (lncRNA), Long intergenic non-coding RNA (lincRNA); these are lncRNAs that do not overlap protein-coding genes and are transcribed independently
01
Overview
Long intergenic non-protein coding RNA 251 (LINC00251) is a member of the long intergenic non-coding RNA (lincRNA) family, representing RNA molecules longer than 200 nucleotides that do not overlap protein-coding genes[7][8][1]. LINC00251 is believed to function in regulating transcription, remodeling chromatin, and stabilizing RNAs, with possible tissue-specific roles in fine-tuning gene expression[7][8][5][3]. LincRNAs such as LINC00251 may participate in enhancer-like activity and other regulatory mechanisms important in cellular differentiation, development, and potentially disease, but its disease relevance and druggability as a therapeutic target are currently unsupported by direct experimental or clinical evidence[1][9]. LINC00251 has several alternative names, including C8orf25 and NCRNA00251[3][5][9].
- Other names
- C8orf25NCRNA00251LINC00251
02
Mechanism of action
Not applicable; no drugs target this RNA, so mechanisms of action are not defined[1][9].
03
Biological functions
Regulation of transcriptionChromatin remodelingRNA stabilizationFine-tuning of gene expression, potentially with tissue specificityPotential enhancer-like activity
04
Disease associations
No direct, widely-documented disease association is established for LINC00251 yet; some lncRNAs are implicated in cancer, but explicit roles for LINC00251 are not currently documented in publicly available sources, although GWAS catalog links suggest possible research into genetic associations[6].
05
Safety considerations
None established; as there are no therapeutics targeting this RNA, no specific safety considerations are noted for LINC00251[1][3][9].
06
Interacting drugs
None established; there are no documented drugs that directly interact with LINC00251[1][9].
07
Biomarkers
None specific; lincRNAs, including LINC00251, may be investigated as biomarkers for gene regulation or disease risk, but LINC00251 itself is not a validated clinical biomarker[1][6].
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 251 (LINC00251).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 251 (LINC00251).